Add to ORKGstatus on the choice of treatment for patients with non-small cell lung cancer; results of a population-based stud
Background and Purpose: Gefitinib is effective in the treatment of advanced non small tell lung canc...
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most...
IntroductionPerformance status (PS) is a standard functional classification in oncology research and...
Objective:To study clinico-radiological profile of patients of lung cancer and to determine the resp...
The KEYNOTE-024 clinical trial showed promising results for pembrolizumab in the first-line of treat...
Performance status (PS) is a commonly used factor in determining the appropriateness for chemotherap...
The aim of the present study was to determine the potential benefit of conventional cisplatin-based ...
In lung cancer, outcome measurement has been mostly limited to survival. Proper assessment of the va...
Free to read at publisher's website. Purpose: Data from two randomized phase III trials were analyze...
The KEYNOTE-024 clinical trial showed promising results for pembrolizumab in the first-line of treat...
<p>Performance of previously published biomarker candidates associated with survival in non-small-ce...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify ...
BackgroundPerformance status (PS) is an important factor in determining survival outcome in non-smal...
Purpose:Data from two randomized phase III trials were analyzed to evaluate prognostic factors and t...
Objectives: New effective therapies are needed to improve the outcome of patients with advanced non-...
Background and Purpose: Gefitinib is effective in the treatment of advanced non small tell lung canc...
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most...
IntroductionPerformance status (PS) is a standard functional classification in oncology research and...
Objective:To study clinico-radiological profile of patients of lung cancer and to determine the resp...
The KEYNOTE-024 clinical trial showed promising results for pembrolizumab in the first-line of treat...
Performance status (PS) is a commonly used factor in determining the appropriateness for chemotherap...
The aim of the present study was to determine the potential benefit of conventional cisplatin-based ...
In lung cancer, outcome measurement has been mostly limited to survival. Proper assessment of the va...
Free to read at publisher's website. Purpose: Data from two randomized phase III trials were analyze...
The KEYNOTE-024 clinical trial showed promising results for pembrolizumab in the first-line of treat...
<p>Performance of previously published biomarker candidates associated with survival in non-small-ce...
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To identify ...
BackgroundPerformance status (PS) is an important factor in determining survival outcome in non-smal...
Purpose:Data from two randomized phase III trials were analyzed to evaluate prognostic factors and t...
Objectives: New effective therapies are needed to improve the outcome of patients with advanced non-...
Background and Purpose: Gefitinib is effective in the treatment of advanced non small tell lung canc...
Malignant tumors of the trachea, bronchi, lungs represent a serious medical and social problem. Most...
IntroductionPerformance status (PS) is a standard functional classification in oncology research and...